What is TiumBio?
TiumBio is a South Korea-based biopharmaceutical firm focused on the discovery and development of innovative small molecule and biologic medicines. The company's pipeline targets critical therapeutic areas including immuno-oncology, fibrosis, endometriosis/uterine fibroids, and hemophilia. Founded and driven by scientific expertise, TiumBio is dedicated to addressing significant unmet medical needs for patients suffering from challenging diseases.
How much funding has TiumBio raised?
TiumBio has raised a total of $29.6M across 1 funding round:
Share Placement
$29.6M
Share Placement (2023): $29.6M, investors not publicly disclosed
What's next for TiumBio?
The recent major enterprise-level funding and strategic investment signal a pivotal phase for TiumBio, likely enabling the acceleration of its clinical and pre-clinical drug candidates. This capital infusion is expected to support further research and development, potentially advancing its pipeline through key milestones and expanding its market reach in the competitive biopharmaceutical landscape. The company's focus on difficult-to-treat diseases positions it for substantial growth and impact.
See full TiumBio company page
